Ignite Creation Date:
2025-12-24 @ 2:53 PM
Ignite Modification Date:
2025-12-25 @ 6:21 PM
Study NCT ID:
NCT06136559
Status:
RECRUITING
Last Update Posted:
2025-12-19
First Post:
2023-11-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-13
Start Date Type:
ACTUAL
Primary Completion Date:
2032-09-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-09-07
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-13
First Submit QC Date:
None
Study First Post Date:
2023-11-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-18
Last Update Post Date:
2025-12-19
Last Update Post Date Type:
ESTIMATED